

**DR. REDDY'S LABORATORIES LIMITED**  
**SCIENCE, TECHNOLOGY AND OPERATIONS COMMITTEE CHARTER**  
*Effective from July 1, 2019*

**1. Primary Objectives**

The Science, Technology and Operations Committee is constituted by, and accountable to, the Board of Directors (or the 'Board') of Dr. Reddy's Laboratories Limited ('DRL' or 'the Company').

Its primary responsibilities are to:

- Review scientific, medical and technical matters and operations involving the company's development and discovery programs (generic and proprietary), including major internal projects and business development opportunities;
- Review the safety and quality of the Company's operations;
- Review and Monitor management actions in creation of Intellectual Property (IP);
- Monitor the status of non-infringement patent challenges; and
- Review and monitor the management's plans and actions in building and nurturing science in the organization.

**2. Composition**

The Committee shall include at least three independent Directors<sup>1</sup>. The Chairman of the Committee shall be designated by the Board.

**3. Secretary**

The Head of IPDO shall act as Secretary to the Committee.

**4. Quorum**

The quorum necessary for transacting business at a meeting of the Committee shall be two members or one-third of the members of the Science, Technology and Operations Committee; whichever is greater.

**5. Meetings**

The Committee will normally meet once during each quarter or at such other time as it may deem necessary and upon management's request.

**6. Authority**

The Committee shall have free access to management and management information. The Committee, at its sole authority, may seek the advice of outside experts or consultants at the company's expense where judged necessary, to discharge its duties and responsibilities.

**7. Specific Responsibilities**

- Review and monitor Company's portfolio, the organic pipeline and technical aspect of business development opportunities and review the long-term strategic goals,

objectives and competencies of the Company's research and development programs and provide guidance to the management accordingly.

- Oversee Company's major technology positions and strategies relative to emerging technologies, emerging concepts of therapy and health care, and changing market requirements.
- Review trends in research and development, and also review emerging technologies for building the Company's technological strength and means to sustain competitiveness;
- Review approaches to acquire and maintain technology positions (including but not limited to contracts, grants, collaborative efforts, alliances, and venture capital); advise the Board on the scientific aspects of major acquisitions and business development transactions.
- Review:-
  - Protection strategies for proprietary intangible assets (patents, know how, data-clinical etc.)
  - Regulatory and payers landscape evolution
  - Impact of R&D strategies on marketing decisions
  - Competitive intelligence on technologies and products
  - Partnerships and alliances with academic centres or companies
  - Company's operations and manufacturing strategies including quality and safety related matters.
- Perform other activities related to this Charter as requested by the Board of Directors or to address issues related to any significant subject within its term of reference.

## **8. Reporting**

The Committee shall report on its activities, and summarize any recommendations; at each quarterly Board meeting. It shall also draft an appropriate report for inclusion in the Company's annual report.

## **9. Evaluation**

- The Committee, if deemed necessary, may conduct a performance evaluation relative to its purpose, duties, responsibilities and effectiveness and recommend, any changes, it considers necessary for the approval of the Board of Directors.
- The Committee may conduct such evaluation and reviews at such intervals and in such manner as it deems appropriate.

## **10. Review of Science and Technology Committee Charter**

The adequacy of this charter shall be reviewed and reassessed by the Committee at such intervals as the Committee deems appropriate and recommendations, if any shall be made to the Board to update the same from time to time.

Approved by: Board of Directors on May 17, 2019

1 Independence of such Directors shall be decided upon by the Board and in accordance with the applicable rules and regulations laid down by the Securities & Exchange Board of India (SEBI), the Companies Act, 2013, the New York Stock Exchange (NYSE), the Securities Exchange Act of 1934 of the United States of America and such other legal and regulatory environment that may be applicable to the Company.